Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease
The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
To maintain treatment blind, two different active patch sizes were used (10 cm\^2 \& 20 cm\^2). Placebo patches matched according to size and appearance. During the trial subjects applied up to three patches, active and placebo, to achieve their assigned daily dose.
Age
30 - No limit years
Sex
ALL
Healthy Volunteers
No
Birmingham, Alabama, United States
Tuscaloosa, Alabama, United States
Gilbert, Arizona, United States
Peoria, Arizona, United States
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Little Rock, Arkansas, United States
Fountain Valley, California, United States
Fresno, California, United States
Irvine, California, United States
Start Date
July 1, 2007
Primary Completion Date
July 1, 2011
Completion Date
July 1, 2011
Last Updated
October 27, 2014
514
ACTUAL participants
Rotigotine
DRUG
Rotigotine
DRUG
Placebo
OTHER
Rotigotine
DRUG
Rotigotine
DRUG
Lead Sponsor
UCB Pharma
NCT02119611
NCT07310264
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07216976